TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT06647420

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Sedative Music
Description: The participants will come twice in person and listen to 9 minutes of sedative music.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Sedative Music
Description: The participants will come twice in person and listen to 9 minutes of sedative music.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Stimulative Music
Description: The participants will come twice in person and listen to 9 minutes of stimulative music.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Stimulative Music
Description: The participants will come twice in person and listen to 9 minutes of stimulative music.
Study: NCT05532046

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BAY2413555 Dose 1
Description: BAY2413555 Dose 1

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BAY2413555 Dose 1
Description: BAY2413555 Dose 1

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BAY2413555 Dose 2
Description: BAY2413555 Dose 2

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo to BAY2413555
Description: Placebo to BAY2413555
Study: NCT05785221

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: General lifestyle and nutritional education
Description: Participants will receive general dietary advice, behavior guidance and nutritional and lifestyle education based on dietary guidelines.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Personalized nutritional and lifestyle weight reduction intervention
Description: Participants will receive personalized dietary advice, behavior guidance and nutritional and lifestyle education by dietitian and physicians. APP-connected wearable devices will be utilized to monitor their dietary intakes, physical activities and sleep conditions and APP-connected scale will be used to monitor their weight changes during interventions.
Study: NCT06325176

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Cryotherapy
Description: During the 1st visit of the patients, they will be assessed for pain and episiotomy wound. The cryotherapy group will include 12 postnatal women. This group will use a bag of ice pack applied to the perineal region. The ice pack will be sealed in plastic bag and wrapped with one layer of a thin cotton tissue so that the skin of the participant would not be in direct contact with ice, which could cause discomfort. During the intervention, the women will be asked to remove their underpants and hygienic pads and remain in the dorsal recumbent position during cryotherapy that lasted 20 minutes. This procedure will be done twice a day for seven consecutive days

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Infrared light therapy
Description: Infrared group will include 12 postnatal women they will encourage to place an infrared lamp at distance of 45 cm from the perineum and the heat produced with 230 volts for twenty minutes. But the mother is checked after the first five minutes to make sure that she was not being burned. The researcher will demonstrate for each woman how to use infrared lamp, and it will be followed by re demonstrations and discussions. These procedures will carry out in the morning and evening for seven consecutive days. The researcher gives the infrared lamp device for each woman then restore it after completion of the study
Study: NCT06558201

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Ketogenic diet
Description: The ketogenic diet (KD) is a normo-caloric diet composed of high-fat, low carbohydrate, and adequate protein intake. The KD will consist of 3 meals a day plus snacks, targeting 75-80% fat, 13-18% protein, 7% carbohydrates.
Study: NCT06539494

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Omeprazole 40 MG
Description: Proton pump inhibitor twice a day for 4 weeks

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Omeprazole 40 MG
Description: Proton pump inhibitor twice a day for 4 weeks
Study: NCT05182931

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dabrafenib 75 MG
Description: Refer arm description

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trametinib 2 MG
Description: Refer arm description
Study: NCT00648479

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: The Guiding Star

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: fluoroscopy (OEC 9800 - General Electric)
Study: NCT06210256

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: unidirectional valve apparatus
Description: In the unidirectional valve group, we attached the unidirectional valve device to the lumen's distal port when one-lung ventilation initiated.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: occluding the non-ventilated endobronchial lumen
Description: In the closed operative lumen group, we closed the lumen's distal port of non-ventilated lung when one-lung ventilation initiated.
Study: NCT04336202

Intervention type: RADIATION
Group type: OTHER
Intervention: External beam radiotherapy + Endorectal brachytherapy
Description: In this study, all participants will receive a treatment of external beam radiotherapy without chemotherapy, which will be followed by three (3) treatments of endorectal brachytherapy with the new applicator.
Study: NCT05157646

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Fitness tracker
Description: Participants will be asked to wear a Fitbit fitness tracker and report their fitness activity to the study team
Study: NCT04782323

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: aQII-1
Description: Biological/Vaccine: Investigational aQII-1 Investigational MF59 Adjuvanted Quadrivalent Influenza vaccine, containing four influenza virus strains (A/H1N1, A/H3N2, B/Yamagata and Victoria lineage) recommended by the WHO (World Health Organization) for quadrivalent vaccines for the respective season.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: aQII-3 Investigational
Description: Biological/Vaccine: Investigational aQII-3 Investigational MF59 Adjuvanted Quadrivalent Influenza vaccine, containing four influenza virus strains (A/H1N1, A/H3N2, B/Yamagata and Victoria lineage) recommended by the WHO (World Health Organization) for quadrivalent vaccines for the respective season.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: aQII-6 Investigational
Description: Biological/Vaccine: Investigational aQII-6 Investigational MF59 Adjuvanted Quadrivalent Influenza vaccine, containing four influenza virus strains (A/H1N1, A/H3N2, B/Yamagata and Victoria lineage) recommended by the WHO (World Health Organization) for quadrivalent vaccines for the respective season.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: aQII-7 Investigational
Description: Biological/Vaccine: Investigational aQII-7 Investigational MF59 Adjuvanted Quadrivalent Influenza vaccine, containing four influenza virus strains (A/H1N1, A/H3N2, B/Yamagata and Victoria lineage) recommended by the WHO (World Health Organization) for quadrivalent vaccines for the respective season.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: aQII-9 Investigational
Description: Biological/Vaccine: Investigational aQII-9 Investigational MF59 Adjuvanted Quadrivalent Influenza vaccine, containing four influenza virus strains (A/H1N1, A/H3N2, B/Yamagata and Victoria lineage) recommended by the WHO (World Health Organization) for quadrivalent vaccines for the respective season.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: aQII-10 Investigational
Description: Biological/Vaccine: Investigational aQII-10 Investigational MF59 Adjuvanted Quadrivalent Influenza vaccine, containing four influenza virus strains (A/H1N1, A/H3N2, B/Yamagata and Victoria lineage) recommended by the WHO (World Health Organization) for quadrivalent vaccines for the respective season.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: aQII-11 Investigational
Description: Biological/Vaccine: Investigational aQII-11 Investigational MF59 Adjuvanted Quadrivalent Influenza vaccine, containing four influenza virus strains (A/H1N1, A/H3N2, B/Yamagata and Victoria lineage) recommended by the WHO (World Health Organization) for quadrivalent vaccines for the respective season.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Licensed QII Active Comparator
Description: Biological/Vaccine: Licensed QII Licensed Quadrivalent Influenza vaccine, containing four influenza virus strains (A/H1N1, A/H3N2, B/Yamagata and Victoria lineage) recommended by the WHO (World Health Organization) for quadrivalent vaccines for the respective season.
Study: NCT05511987

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Madela THOPAZ Digital Device
Description: Digital drainage systems use electronic sensors to measure changes in pressure and thus may allow for quantification of the degree of air leak continuously and provide a graphical representation of the trend over time. Data on intrapleural pressure are also provided by some units. Together, these data may lead to expedited chest tube removal and hospital discharge with obvious financial implications.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Atrium Analog Device
Description: Analog drainage systems contain a sequentially numbered series of columns in the water seal chamber. The degree of air leak is assessed by observing the highest numbered column in which bubbling occurs. This provides a qualitative assessment at a specific point in time. This assessment, however, is subject to interobserver variability and does not account for variation over time.
Study: NCT05558059

Intervention type: DEVICE
Intervention: Handheld Optical Coherence Tomography with OCT Angiography
Description: OCT systems are in vivo optical imaging technology that allows non-contact imaging of early-stage ocular pathology. They create real-time, non-invasive images of ocular microstructure and have become standard-of-care instruments in ophthalmic imaging in clinics and operating rooms. In contrast to the visible light used in clinical eye examinations, because infrared light is not visible, the participant is not disturbed by the light. OCT imaging allows the capture of hundreds of B-scan (cross-sectional) images in seconds. These B-scans are analyzed for depth-resolved information and can also be stacked to create a volume and the stack may be summed up to create a retinal image.~OCT angiography (OCTA) is an extension of the OCT systems, by taking images at the same location over time to extract retinal vascular flow information. It has been utilized to assess the ocular blood flow in many adult and pediatric patients.
Study: NCT05182931

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trametinib 2 MG
Description: Refer arm description
Study: NCT06539091

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fluzoparib
Description: The study treatment was followed by a 3-week treatment cycle. First day of each dosing cycle, subjects are required to complete various examinations, including vital signs, physical examination, laboratory examination, physical status score, and BMD testing to evaluate the safety and tolerability of continued treatment.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Apatinib Mesylate
Description: The study treatment was followed by a 3-week treatment cycle. First day of each dosing cycle, subjects are also required to complete various examinations, including vital signs, physical examination, laboratory examination, physical status score, and BMD testing to evaluate the safety and tolerability of continued treatment.
Study: NCT06538103

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Eye soft surgery
Description: Early lower eyelid surgery will be performed in accordance with the protocol previously described by Di Stadio, with medial or lateral eyelid lifting surgery as indicated. The indication for eye surgery are in case of ectropion (exposure of the conjunctiva due to a reduction in tension of the anterior compartment of the eye muscle) and lagophthalmos (incomplete /abnormal closure of the eye with eyelid in closed position) a lateral lower eyelid lifting surgery is performed. otherwise, in presence of epiphora (the eversion of the lachrymal point) and lagophthalmos medial lower eyelid lifting surgery is done.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Physical Rehabilitation
Description: Kabat therapy and neuromuscular reeducation (NMR) at home Kabat therapy involved thrice-weekly 35-minute sessions.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Physical Rehabilitation
Description: Kabat therapy and neuromuscular reeducation (NMR) at home Kabat therapy involved thrice-weekly 35-minute sessions.
Study: NCT05101356

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Antineoplastic Vaccine
Description: Given LabVax 3(22)-23 ID

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Antineoplastic Vaccine
Description: Given LabVax 3(22)-23 ID

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Sargramostim
Description: Given SC

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Sargramostim
Description: Given SC

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Given IV per standard of care
Study: NCT04767217

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: artemether-lumefantrine (ALN)
Description: Assessing the efficacy on current 1st line antimalarial, and an alternative 1st line or 2nd line medicine

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: dihydroartemisinin-piperaquine (DHA-PPQ)
Description: dihydroartemisinin-piperaquine (DHA-PPQ)
Study: NCT06224478

Intervention type: OTHER
Intervention: Measurement of palatal mucosa thickness on CBCT scans
Description: Measurement of palatal mucosa thickness on CBCT scans in hypodovergent, normodivergent and hyperdivergent patients

Intervention type: OTHER
Intervention: Measurement of palatal mucosa thickness on CBCT scans
Description: Measurement of palatal mucosa thickness on CBCT scans in hypodovergent, normodivergent and hyperdivergent patients

Intervention type: OTHER
Intervention: Measurement of palatal mucosa thickness on CBCT scans
Description: Measurement of palatal mucosa thickness on CBCT scans in hypodovergent, normodivergent and hyperdivergent patients
Study: NCT04727619

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: SLEEP program
Description: SLEEP is a 6-week educational program designed to improve sleep hygiene and habits.
Study: NCT06133764

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Enucleation+ Peripheral Ostectomy+Carnoy's solution chemical cauterization (E+CS + PO)
Description: The enucleation procedures, which were meticulously carried out in order to remove the odontogenic keratocyst in one piece without breaking its lining or leaving any epithelial remnants.The peripheral ostectomy treatment will be carried out with a large spherical bur and plenty of irrigation.After filling the bone cavity with more sterile gauze, the Carnoy's solution was slowly injected into it with a plastic syringe. The gauze was continuously injected with CS until it was fully saturated without leaking too much into the surrounding tissues. The CS was held in place for 3 minutes.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Decompression/ marsupialization (D/M)
Description: A surgical window will be created in the cyst wall to drain the contents while retaining continuity between the cyst and the oral cavity

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Enucleation (E)
Description: The enucleation will be accomplished in the same manner that it will be performed in the group of Enucleation+ Peripheral Ostectomy+Carnoy's solution chemical cauterization (E+ PO+ CS).

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Enucleation+Carnoy's solution (E+CS)
Description: Both enucleation and Carnoy's solution will be carried out as planned in the group Enucleation+ Peripheral Ostectomy+Carnoy's solution chemical cauterization (E+ PO+ CS).

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Enucleation+ Peripheral Ostectomy (E+ PO)
Description: Both enucleation and peripheral ostectomy will be carried out as planned in the group Enucleation+ Peripheral Ostectomy+ Carnoy's solution chemical cauterization (E+ PO+ CS).
Study: NCT06572670

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Progressive relaxation exercise before coronary angiography
Description: Patients in the intervention group will undergo progressive relaxation before undergoing angiography.
Study: NCT06215638

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bortezomib
Description: Bortezomib 2 mg per week subcutaneously, for twelve weeks in total
Study: NCT05599594

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Aromatherapy
Description: 6 drops of aromatic oils used by the researcher will be dripped by the aromatic oils to take the fragrance by inhalation for 30 minutes.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Aromatherapy
Description: 6 drops of aromatic oils used by the researcher will be dripped by the aromatic oils to take the fragrance by inhalation for 30 minutes.
Study: NCT04701021

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: TENDU
Description: The vaccine is administrated by subcutaneous injections, one injection per drug substance (four separate injections) consecutively.
Study: NCT05843968

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rituximab
Description: 2 doses of rituximab 375 mg/m\^2(maximum 500mg/day) at 6 months intervals.~Half an hour before rituximab infusion: oral acetaminophen 15mg/kg, oral or intramuscular antihistamine, methylprednisolone 2mg/kg IV. Trimethoprim-sulfamethoxazole should be administered orally from the initiation of rituximab therapy until peripheral-blood B cell recovery to prevent pneumocystis infection.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Mycophenolate Mofetil
Description: Mycophenolate Mofetil 20-30 mg/kg/day BID,then adjust the dosage of drugs(maximum 2g/day) to maintian the concentration for MPA-AUC is 30-50μg.h/ml. Total duration:1year.~Steroids dose:1.5mg/kg(maximum 40mg) qod for 2 weeks and gradually taper by 0.3 mg/kg every 2 weeks
Study: NCT06045624

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: OR-101 (Single ascending dose)
Description: SAD participants will receive either placebo or one of planned doses levels of 15mg, 45mg, 150mg, 450mg, 900mg, 1500mg OR-101 in dose escalating manner in cohorts 1-6.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: OR-101 (Food effect)
Description: Food effect participants (8 subjects in 9 cohorts) will only receive OR-101with a high fat meal prior to administration and subjects in corresponding dose under fasted condition will serve as their reference group

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: OR-101 (Multiple ascending dose)
Description: MAD participants will receive either placebo or one of planned doses levels of 15mg, 45mg, 135mg, 270mg, 540mg and 900mg OR-101 in dose escalating manner in cohorts 1-6. Total dosage of cohort 7 and 8 will be decided based on Safety review committe's input where cohort 8 will receive this daily for 7 days

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Participants will receive matching placebo across Part A and C of the study
Study: NCT06052969

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Pulse NanoMED System
Description: The Pulse NanoMED System is comprised of iron nanoparticles and a small, portable, magnetic Workstation.
Study: NCT05052970

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mitoxantrone Hydrochloride Liposome injection
Description: Mitoxantrone Hydrochloride Liposome injection will be administered by an intravenous infusion on day 1 of each 28-day cycle

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mitoxantrone Hydrochloride Liposome injection
Description: Mitoxantrone Hydrochloride Liposome injection will be administered by an intravenous infusion on day 1 of each 28-day cycle

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mitoxantrone Hydrochloride Liposome injection
Description: Mitoxantrone Hydrochloride Liposome injection will be administered by an intravenous infusion on day 1 of each 28-day cycle

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bortezomib for Injection
Description: Bortezomib (1.3 mg/m\^2) will be administered by an intravenous injection or subcutaneously on day 1,4,8,11of each 28-day cycle

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bortezomib for Injection
Description: Bortezomib (1.3 mg/m\^2) will be administered by an intravenous injection or subcutaneously on day 1,4,8,11of each 28-day cycle

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bortezomib for Injection
Description: Bortezomib (1.3 mg/m\^2) will be administered by an intravenous injection or subcutaneously on day 1,4,8,11of each 28-day cycle

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone Acetate Tablets
Description: Dexamethasone (20 mg/d) will be taken orally on day 1,2,4,5,8,9,11,12 of each 28-day cycle

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone Acetate Tablets
Description: Dexamethasone (20 mg/d) will be taken orally on day 1,2,4,5,8,9,11,12 of each 28-day cycle

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone Acetate Tablets
Description: Dexamethasone (20 mg/d) will be taken orally on day 1,2,4,5,8,9,11,12 of each 28-day cycle
Study: NCT05676411

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Benzoyl Peroxide Topical
Description: Topical benzoyl peroxide cream will be applied to the shoulder skin twice a day for 2 days leading up to and in the morning of surgery.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Electrocautery surgical skin incision
Description: The skin incision will be made entirely using electrocautery at the beginning of shoulder replacement.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Electrocautery surgical skin incision
Description: The skin incision will be made entirely using electrocautery at the beginning of shoulder replacement.
Study: NCT05046457

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Beta-cryptoxanthin (BCX)
Description: Subjects will be randomised into one of the three study treatment arms.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Beta-cryptoxanthin (BCX)
Description: Subjects will be randomised into one of the three study treatment arms.
Study: NCT04736602

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Triptorelin pamoate 15mg
Description: Intramuscular injection (IM)